SEC Info℠

Home

Search

My Interests

Help

Sign In

Please Sign In

Intellia Therapeutics, Inc. – ‘8-K’ for 4/3/20 – ‘EX-3.1’

On:  Thursday, 4/9/20, at 5:01pm ET   ·   For:  4/3/20   ·   Accession #:  1564590-20-16142   ·   File #:  1-37766

Previous ‘8-K’:  ‘8-K’ on / for 3/26/20   ·   Next:  ‘8-K’ on / for 5/7/20   ·   Latest:  ‘8-K’ on / for 5/9/24   ·   10 References:   By:  Intellia Therapeutics, Inc. – ‘10-K’ on 2/23/23 for 12/31/22 By:  Intellia Therapeutics, Inc. – ‘424B5’ on 12/1/22 By:  Intellia Therapeutics, Inc. – ‘424B5’ on 3/4/22 By:  Intellia Therapeutics, Inc. – ‘10-K’ on 2/24/22 for 12/31/21 By:  Intellia Therapeutics, Inc. – ‘424B5’ on 7/1/21 By:  Intellia Therapeutics, Inc. – ‘424B5’ on 6/28/21 By:  Intellia Therapeutics, Inc. – ‘10-K’ on 2/26/21 for 12/31/20 By:  Intellia Therapeutics, Inc. – ‘424B5’ on 12/2/20 By:  Intellia Therapeutics, Inc. – ‘424B5’ on 11/30/20 By:  Intellia Therapeutics, Inc. – ‘S-3ASR’ on 11/30/20 

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

 Text Wildcards:  ? (any letter/digit),  * (many).  Search Logic:  for Documents:  & (and),  | (or);  for Text:  | (anywhere),  "(&)" (near).  Details... 

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/09/20  Intellia Therapeutics, Inc.       8-K:5,9     4/03/20   11:173K                                   ActiveDisclosure/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     35K 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML      9K 
 9: R1          Document and Entity Information                     HTML     50K 
 6: XML         IDEA XML File -- Filing Summary                      XML     11K 
 8: XML         XBRL Instance -- ntla-8k_20200403_htm                XML     15K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- ntla-20200403_lab                     XML     60K 
 5: EX-101.PRE  XBRL Presentations -- ntla-20200403_pre              XML     36K 
 3: EX-101.SCH  XBRL Schema -- ntla-20200403                         XSD     18K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               13±    20K 
11: ZIP         XBRL Zipped Folder -- 0001564590-20-016142-xbrl      Zip     11K 

Exhibit 3.1

AMENDMENT TO THE

SECOND AMENDED AND RESTATED

BY-LAWS

OF

INTELLIA THERAPEUTICS, INC.

(the “Corporation”)

Section 8 of Article VI of the Second Amended and Restated By-laws of the Corporation (the “By-laws”) is hereby amended and restated in its entirety to read as follows:

“SECTION 8. Exclusive Jurisdiction of Delaware Courts or the United States District Court for the District of Massachusetts. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of or based on a fiduciary duty owed by any current or former director, officer or other employee of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim against the Corporation or any current or former director, officer, or other employee or stockholder of the Corporation arising pursuant to any provision of the Delaware General Corporation Law or the Certificate or By-laws, or (iv) any action asserting a claim against the Corporation governed by the internal affairs doctrine. Unless the Corporation consents in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 8.”

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/23/23  Intellia Therapeutics, Inc.       10-K       12/31/22   88:16M                                    Donnelley … Solutions/FA
12/01/22  Intellia Therapeutics, Inc.       424B5                  2:526K                                   Donnelley … Solutions/FA
 3/04/22  Intellia Therapeutics, Inc.       424B5                  2:547K                                   Donnelley … Solutions/FA
 2/24/22  Intellia Therapeutics, Inc.       10-K       12/31/21   86:19M                                    Donnelley … Solutions/FA
 7/01/21  Intellia Therapeutics, Inc.       424B5                  1:604K                                   Donnelley … Solutions/FA
 6/28/21  Intellia Therapeutics, Inc.       424B5                  1:601K                                   Donnelley … Solutions/FA
 2/26/21  Intellia Therapeutics, Inc.       10-K       12/31/20   81:13M                                    ActiveDisclosure/FA
12/02/20  Intellia Therapeutics, Inc.       424B5                  1:586K                                   Donnelley … Solutions/FA
11/30/20  Intellia Therapeutics, Inc.       424B5                  1:585K                                   Donnelley … Solutions/FA
11/30/20  Intellia Therapeutics, Inc.       S-3ASR     11/30/20    5:913K                                   Donnelley … Solutions/FA